| Medical and Health Sciences | Lifetime | 4 | US 3 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 6 | US 4 | 100.00 |
| Hematology | Lifetime | 1 | US 1 | 100.00 |
| Medical Genetics | Lifetime | 1 | US 1 | 99.99 |
| Public, Environmental and Occupational Health | Lifetime | 12 | US 9 | 99.98 |
| Molecular Biology | Lifetime | 360 | US 227 | 99.83 |
| Rheumatology | Lifetime | 52 | US 19 | 99.75 |
| Oncology | Lifetime | 173 | US 93 | 99.71 |
| Pathology and Forensic Medicine | Lifetime | 136 | US 74 | 99.42 |
| Immunology | Lifetime | 859 | US 435 | 97.18 |
| Public, Environmental and Occupational Health | 2021-2025 | 2 | US 2 | 99.98 |
| Hematology | 2021-2025 | 1 | US 1 | 99.99 |
| Medical Genetics | 2021-2025 | 9 | US 4 | 99.76 |
| Molecular Biology | 2021-2025 | 391 | US 107 | 98.09 |
| Oncology | 2021-2025 | 228 | US 97 | 98.08 |
| Pathology and Forensic Medicine | 2021-2025 | 277 | US 94 | 91.25 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 573 | US 236 | 83.22 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 1 | US 1 | 100.00 |
| Acute Myeloid Leukemia Research | Lifetime | 1 | US 1 | 100.00 |
| Acute Lymphoblastic Leukemia research | Lifetime | 1 | US 1 | 100.00 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 1 | US 1 | 100.00 |
| Eosinophilic Disorders and Syndromes | Lifetime | 1 | US 1 | 100.00 |
| Lymphoma Diagnosis and Treatment | Lifetime | 3 | US 2 | 99.97 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 1 | US 1 | 99.98 |
| Neutropenia and Cancer Infections | Lifetime | 1 | US 1 | 99.95 |
| Histone Deacetylase Inhibitors Research | Lifetime | 2 | US 2 | 99.96 |
| Retinoids in leukemia and cellular processes | Lifetime | 6 | US 5 | 99.88 |
| CAR-T cell therapy research | Lifetime | 22 | US 13 | 99.86 |
| Epigenetics and DNA Methylation | Lifetime | 37 | US 26 | 99.82 |
| Multiple Myeloma Research and Treatments | Lifetime | 20 | US 13 | 99.84 |
| Childhood Cancer Survivors' Quality of Life | Lifetime | 34 | US 27 | 99.62 |
| Hematological disorders and diagnostics | Lifetime | 13 | US 10 | 99.60 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 45 | US 20 | 99.68 |
| Economic and Financial Impacts of Cancer | Lifetime | 18 | US 13 | 99.55 |
| Protein Degradation and Inhibitors | Lifetime | 30 | US 18 | 99.67 |
| Kruppel-like factors research | Lifetime | 13 | US 5 | 99.44 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 73 | US 46 | 99.58 |
| Cancer therapeutics and mechanisms | Lifetime | 75 | US 50 | 99.43 |
| Blood disorders and treatments | Lifetime | 71 | US 37 | 98.64 |
| HER2/EGFR in Cancer Research | Lifetime | 194 | US 94 | 99.11 |
| Pharmaceutical Economics and Policy | Lifetime | 120 | US 67 | 97.98 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 251 | US 115 | 98.51 |
| Cancer Genomics and Diagnostics | Lifetime | 768 | US 413 | 98.63 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 692 | US 318 | 98.44 |
| Advanced Breast Cancer Therapies | Lifetime | 174 | US 85 | 98.51 |
| Cancer Treatment and Pharmacology | Lifetime | 576 | US 288 | 98.43 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 418 | US 192 | 97.73 |
| Vascular Tumors and Angiosarcomas | Lifetime | 172 | US 87 | 97.54 |
| Drug-Induced Ocular Toxicity | Lifetime | 37 | US 23 | 96.42 |
| Platelet Disorders and Treatments | Lifetime | 537 | US 208 | 97.21 |
| Mast cells and histamine | Lifetime | 339 | US 126 | 96.50 |
| Fungal Infections and Studies | Lifetime | 483 | US 190 | 96.92 |
| Lung Cancer Research Studies | Lifetime | 931 | US 381 | 97.03 |
| Neuroblastoma Research and Treatments | Lifetime | 689 | US 339 | 96.71 |
| Antifungal resistance and susceptibility | Lifetime | 884 | US 318 | 96.06 |
| Bone and Joint Diseases | Lifetime | 623 | US 245 | 95.54 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 335 | US 154 | 96.03 |
| Fungal Plant Pathogen Control | Lifetime | 374 | US 95 | 93.84 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 925 | US 492 | 93.69 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 901 | US 351 | 92.70 |
| Gestational Trophoblastic Disease Studies | Lifetime | 341 | US 146 | 90.20 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 820 | US 339 | 88.48 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 1 | US 1 | 99.97 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 1 | US 1 | 100.00 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 1 | US 1 | 99.99 |
| Acute Myeloid Leukemia Research | 2021-2025 | 2 | US 2 | 99.99 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 1 | US 1 | 99.89 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 2 | US 2 | 99.89 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 6 | US 4 | 99.77 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 28 | US 15 | 99.56 |
| CAR-T cell therapy research | 2021-2025 | 53 | US 26 | 99.61 |
| Neutropenia and Cancer Infections | 2021-2025 | 7 | US 4 | 98.81 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 4 | US 4 | 98.75 |
| Protein Degradation and Inhibitors | 2021-2025 | 29 | US 14 | 99.39 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 31 | US 17 | 99.08 |
| Hematological disorders and diagnostics | 2021-2025 | 6 | US 5 | 97.00 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 109 | US 55 | 98.57 |
| Childhood Cancer Survivors' Quality of Life | 2021-2025 | 223 | US 120 | 95.84 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 274 | US 68 | 89.28 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 199 | US 71 | 91.55 |
| Bone and Joint Diseases | 2021-2025 | 453 | US 71 | 81.35 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 376 | US 53 | 71.79 |
| Polyomavirus and related diseases | 2021-2025 | 868 | US 285 | 71.85 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 781 | US 251 | 57.75 |
| Kruppel-like factors research | 2021-2025 | 787 | US 164 | 50.89 |
